# A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT04657302** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 30 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Glofitamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04657302
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2022-10-25
- **Final completion:** 2024-01-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657302, "A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04657302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*